Motif Bio (LON:MTFB)‘s stock had its “buy” rating reaffirmed by investment analysts at FinnCap in a research report issued on Thursday, November 16th. They presently have a GBX 100 ($1.35) price objective on the stock. FinnCap’s price target indicates a potential upside of 173.97% from the company’s previous close.
Several other research firms also recently issued reports on MTFB. Northland Securities restated a “buy” rating on shares of Motif Bio in a report on Wednesday, November 15th. Peel Hunt restated a “buy” rating and set a GBX 106 ($1.43) price objective on shares of Motif Bio in a report on Wednesday, November 15th. Finally, Beaufort Securities restated a “speculative buy” rating and set a GBX 110 ($1.48) price objective on shares of Motif Bio in a report on Monday, October 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Motif Bio has an average rating of “Buy” and an average price target of GBX 101.50 ($1.37).
Motif Bio (MTFB) traded up GBX 1.50 ($0.02) during mid-day trading on Thursday, reaching GBX 36.50 ($0.49). The company’s stock had a trading volume of 1,133,958 shares, compared to its average volume of 1,200,000. Motif Bio has a 52 week low of GBX 22 ($0.30) and a 52 week high of GBX 51.75 ($0.70).
TRADEMARK VIOLATION NOTICE: “Motif Bio (MTFB) Receives Buy Rating from FinnCap” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/motif-bio-plc-mtfb-stock-rating-reaffirmed-by-finncap.html.
About Motif Bio
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio plc and related companies with MarketBeat.com's FREE daily email newsletter.